ArticlePloS one2012
The inhibition of anti-DNA binding to DNA by nucleic acid binding polymers.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Cell-Free DNA-Based Theranostics for Inflammatory Disorders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Treating acute lung injury through scavenging of cell-free DNA by cationic nanoparticles.Materials today. Bio · 2024Article
- Synthetic polypeptides inhibit nucleic acid-induced inflammation in autoimmune diseases by disrupting multivalent TLR9 binding to LL37-DNA bundles.Nature nanotechnology · 2024Article
- Intranasal PAMAM-G3 scavenges cell-free DNA attenuating the allergic airway inflammation.Cell death discovery · 2024Article
- Mixed-surface polyamidoamine polymer variants retain nucleic acid-scavenger ability with reduced toxicity.iScience · 2022Article
- Nanoparticulate cell-free DNA scavenger for treating inflammatory bone loss in periodontitis.Nature communications · 2022Article
- Targeting DAMPs with nucleic acid scavengers to treat lupus.Translational research : the journal of laboratory and clinical medicine · 2022Review
- β-Cyclodextrin-containing polymer treatment of cutaneous lupus and influenza improves outcomes.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Circulating Free DNA and Its Emerging Role in Autoimmune Diseases.Journal of personalized medicine · 2021Review
- Cationic Nanomaterials for Autoimmune Diseases Therapy.Frontiers in pharmacology · 2021Review
- Treatment of severe sepsis with nanoparticulate cell-free DNA scavengers.Science advances · 2020Article
- Cationic nanoparticle as an inhibitor of cell-free DNA-induced inflammation.Nature communications · 2018Article
- Theranostic Nucleic Acid Binding Nanoprobe Exerts Anti-inflammatory and Cytoprotective Effects in Ischemic Injury.Theranostics · 2017Article
- Scavenging nucleic acid debris to combat autoimmunity and infectious disease.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- The Use of Poly-L-Lysine as a Capture Agent to Enhance the Detection of Antinuclear Antibodies by ELISA.PloS one · 2016Article
- Polymeric drugs: Advances in the development of pharmacologically active polymers.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- The effect of polyamines on the binding of anti-DNA antibodies from patients with SLE and normal human subjects.Clinical immunology (Orlando, Fla.) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Antibodies to DNA (anti-DNA) are the serological hallmark of systemic lupus erythematosus (SLE) and can mediate disease pathogenesis by the formation of immune complexes. Since blocking immune complex formation can attenuate disease manifestations, the effects of nucleic acid binding polymers (NABPs) on anti-DNA binding in vitro were investigated. The compounds tested included polyamidoamine dendrimer, 1,4-diaminobutane core, generation 3.0 (PAMAM-G3), hexadimethrine bromide, and a β-cylodextrin-containing polycation. As shown with plasma from patients with SLE, NABPs can inhibit anti-DNA antibody binding in ELISA assays. The inhibition was specific since the NABPs did not affect binding to tetanus toxoid or the Sm protein, another lupus autoantigen. Furthermore, the polymers could displace antibody from preformed complexes. Together, these results indicate that NABPs can inhibit the formation of immune complexes and may represent a new approach to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.